Genetic Technologies (GENE) announced that the Company is forming a strategic alliance with QIAGEN (QGEN). The alliance will establish and develop a ‘Centre of Excellence’ facility in Australia initially servicing Australia and New Zealand with potential for expansion, showcasing the Life Science and Diagnostics expertise of both organizations throughout the region. The partnership will further enhance GTG’s reputation as a regional leader in precision medicine in predicative and consumer genomics, utilizing QIAGEN technologies.The relationship is expected to open a wide range of new commercial opportunities for GTG with enhanced automation capability and increased capacity supporting long-term revenue growth. Additionally, this initiative will unlock the Australian reimbursable market for all testing categories, including the geneType hereditary cancer test. This will make the geneType Breast, Ovarian and Colorectal cancer tests the most comprehensive offering in the market later in 2023. Gaining reimbursement coverage for geneType cancer assessment tests is expected to accelerate the adoption of these tests by General Practice clinics where patients are able to undertake the test with minimal out-of-pocket expenses. QIAGEN will support the enhancement of GTG capabilities through software, hardware, consumable and technical solutions, including: the reagents and QIAGEN’s proprietary QCII software to complete Next Generation Sequencing validation in house. The rollout will include QIAGEN’s QIAseq targeted DNA Pro Sample to Insight solutions for NGS Oncology and customized inhouse data analysis tools to provide sample to result service for GTG customers; collection devices, hardware, reagents and panels to equip GTG with the required laboratory scale to perform tests in-house; capability to multiplex on different scalable platforms; and provide technical support and the establishment of protocols for GTG to perform the tests for NATA accreditation for QIAGEN related Technologies.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GENE:
- Genetic Technologies reports Q2 receipts A$2.4M, up 32% from 2Q22
- Quarterly Business Update – December 2022; Sixth Consecutive Quarter of Growth
- Genetic Technologies presents data on colorectal cancer risk prediction model
- Genetic Technologies provides update on 2023 priorities
- Genetic Technologies publishes paper on geneType Multi-Risk test